Skip to content
MMDLRadar

Products Liability

Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation

Products LiabilityNewly CentralizedMDL 3163

Pending actions

200

Historical total

200

Resolved / remanded

0

Share of caseload still pending100%

Newly Centralized. Consolidated within the last 18 months. Of 200 lawsuits ever part of this litigation, 200 remain active.

About this litigation

Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation is a federal multidistrict litigation classified by the Judicial Panel on Multidistrict Litigation as a Products Liability docket. It was centralized on December 15, 2025 before Karen S. Marston, U.S. District Judge, in the E.D. Pennsylvania.

As of the August 3, 2026 JPML report, 200 individual lawsuits are pending in this MDL. Cases coordinated in an MDL keep their separate identity — they are managed together only for pretrial proceedings. Learn how MDLs work.